Germany Cancer Diagnostics Market Size & Outlook
Germany cancer diagnostics market, 2018-2030 (US$M)
Related Markets
Germany cancer diagnostics market highlights
- The Germany cancer diagnostics market generated a revenue of USD 6,057.9 million in 2023 and is expected to reach USD 9,637.9 million by 2030.
- The Germany market is expected to grow at a CAGR of 6.9% from 2024 to 2030.
- In terms of segment, consumables was the largest revenue generating product in 2023.
- Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2023 | USD 6,057.9 million |
| Market revenue in 2030 | USD 9,637.9 million |
| Growth rate | 6.9% (CAGR from 2023 to 2030) |
| Largest segment | Consumables |
| Fastest growing segment | Consumables |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Services, Instruments, Consumables |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, Germany accounted for 5.6% of the global cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- Germany is the fastest growing regional market in Europe and is projected to reach USD 9,637.9 million by 2030.
Consumables was the largest segment with a revenue share of 60.05% in 2023. Horizon Databook has segmented the Germany cancer diagnostics market based on services, instruments, consumables covering the revenue growth of each sub-segment from 2018 to 2030.
In Germany, Merck and Sysmex Inostics were the first to receive CE approval for liquid biopsy tests for patients with colorectal cancer. Furthermore, intense competition between biotechnology companies, such as Epigenomics and Roche, is expected to boost market growth.
Increasing collaborations between key market players in this region are expected to fuel market growth through an increase in R&D opportunities for better test procedures. For instance, in October 2020, Oncocyte entered into a licensing and collaboration agreement with Chronix Biomedical for liquid biopsy technology.
Furthermore, in January 2023, Mainz Biomed announced plans to launch a Corporate Health Program in Germany for ColoAlert, a screening test for colorectal cancer. However, the high costs of these tests may be a challenge for market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Germany cancer diagnostics market size, by product, 2018-2030 (US$M)
Germany Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
